Morepen Laboratories Limited (MOREPENLAB.BO)
INR 50.19
(4.3%)
INR 50.19
(4.3%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 17.01 Billion INR | 19.55% |
| 2022 | 14.13 Billion INR | -8.28% |
| 2021 | 15.41 Billion INR | 31.16% |
| 2020 | 11.75 Billion INR | 39.99% |
| 2019 | 8.39 Billion INR | 11.03% |
| 2018 | 7.56 Billion INR | 26.51% |
| 2017 | 5.97 Billion INR | 1.93% |
| 2016 | 5.86 Billion INR | 20.89% |
| 2015 | 4.85 Billion INR | 21.08% |
| 2014 | 4 Billion INR | 9.21% |
| 2013 | 3.66 Billion INR | 12.56% |
| 2012 | 3.25 Billion INR | 12.64% |
| 2011 | 2.89 Billion INR | 26.74% |
| 2010 | 2.28 Billion INR | 7.6% |
| 2009 | 2.12 Billion INR | 14.4% |
| 2008 | 1.85 Billion INR | 25.52% |
| 2007 | 1.47 Billion INR | -13.48% |
| 2006 | 1.7 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 4.55 Billion INR | 7.6% |
| 2023 Q1 | 4.01 Billion INR | 11.36% |
| 2023 FY | 16.9 Billion INR | 19.55% |
| 2023 Q4 | 4.23 Billion INR | -4.83% |
| 2023 Q3 | 4.44 Billion INR | 5.4% |
| 2023 Q2 | 4.21 Billion INR | 5.17% |
| 2022 Q3 | 3.48 Billion INR | -13.53% |
| 2022 Q1 | 3.02 Billion INR | -16.7% |
| 2022 Q2 | 4.02 Billion INR | 33.26% |
| 2022 FY | 14.13 Billion INR | -8.28% |
| 2022 Q4 | 3.6 Billion INR | 3.34% |
| 2021 FY | 15.41 Billion INR | 31.16% |
| 2021 Q3 | 3.96 Billion INR | 0.3% |
| 2021 Q4 | 3.63 Billion INR | -8.44% |
| 2021 Q1 | 3.86 Billion INR | 41.19% |
| 2021 Q2 | 3.95 Billion INR | 2.22% |
| 2020 Q2 | 3.36 Billion INR | 30.57% |
| 2020 FY | 11.75 Billion INR | 39.99% |
| 2020 Q1 | 2.57 Billion INR | 33.4% |
| 2020 Q4 | 2.73 Billion INR | -10.9% |
| 2020 Q3 | 3.07 Billion INR | -8.61% |
| 2019 FY | 8.39 Billion INR | 11.03% |
| 2019 Q1 | 2.02 Billion INR | -1.65% |
| 2019 Q2 | 2.13 Billion INR | 5.15% |
| 2019 Q3 | 2.3 Billion INR | 7.79% |
| 2019 Q4 | 1.93 Billion INR | -16.05% |
| 2018 Q3 | 2.12 Billion INR | 21.97% |
| 2018 FY | 7.56 Billion INR | 26.51% |
| 2018 Q2 | 1.73 Billion INR | 6.23% |
| 2018 Q4 | 2.06 Billion INR | -2.72% |
| 2018 Q1 | 1.63 Billion INR | 0.63% |
| 2017 Q3 | 1.54 Billion INR | 3.38% |
| 2017 Q4 | 1.62 Billion INR | 5.14% |
| 2017 FY | 5.97 Billion INR | 1.93% |
| 2017 Q1 | 1.3 Billion INR | 0.0% |
| 2017 Q2 | 1.49 Billion INR | 14.6% |
| 2016 FY | 5.86 Billion INR | 20.89% |
| 2015 FY | 4.85 Billion INR | 21.08% |
| 2014 FY | 4 Billion INR | 9.21% |
| 2013 FY | 3.66 Billion INR | 12.56% |
| 2012 Q1 | - INR | 0.0% |
| 2012 FY | 3.25 Billion INR | 12.64% |
| 2012 Q2 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2011 FY | 2.89 Billion INR | 26.74% |
| 2010 FY | 2.28 Billion INR | 7.6% |
| 2009 FY | 2.12 Billion INR | 14.4% |
| 2008 FY | 1.85 Billion INR | 25.52% |
| 2007 FY | 1.47 Billion INR | -13.48% |
| 2006 FY | 1.7 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 96.491% |
| NATCO Pharma Limited | 40.02 Billion INR | 57.474% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -61.877% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -556.485% |
| Achyut Healthcare Limited | 61.36 Million INR | -27632.23% |
| Ajanta Pharma Limited | 42.08 Billion INR | 59.562% |
| Alkem Laboratories Limited | 126.67 Billion INR | 86.565% |
| Alpa Laboratories Limited | 1.08 Billion INR | -1465.123% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 72.155% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -31.367% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 94.071% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -259.492% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -120.956% |
| Brooks Laboratories Limited | 794.86 Million INR | -2041.128% |
| Divi's Laboratories Limited | 78.45 Billion INR | 78.306% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 93.904% |
| Eris Lifesciences Limited | 20.09 Billion INR | 15.292% |
| FDC Limited | 19.42 Billion INR | 12.406% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 85.593% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 25.46% |
| Granules India Limited | 45.06 Billion INR | 62.233% |
| Gufic Biosciences Limited | 8.06 Billion INR | -110.979% |
| Hester Biosciences Limited | 3.04 Billion INR | -458.832% |
| Indoco Remedies Limited | 17.89 Billion INR | 4.893% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -32.867% |
| Ipca Laboratories Limited | 76.22 Billion INR | 77.672% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -715.469% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -3275.344% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -1531.187% |
| Laurus Labs Limited | 50.01 Billion INR | 65.974% |
| Lupin Limited | 200.1 Billion INR | 91.495% |
| Mankind Pharma Limited | 103.34 Billion INR | 83.532% |
| Medicamen Biotech Limited | 1.79 Billion INR | -849.158% |
| Medico Remedies Limited | 1.44 Billion INR | -1074.366% |
| Megasoft Limited | 373.95 Million INR | -4451.105% |
| Piramal Pharma Limited | 81.71 Billion INR | 79.172% |
| RPG Life Sciences Limited | 5.82 Billion INR | -192.397% |
| Sigachi Industries Limited | 3.98 Billion INR | -326.588% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -2152.819% |
| Unichem Laboratories Limited | 16.57 Billion INR | -2.684% |
| Wanbury Limited | 5.75 Billion INR | -195.648% |
| Windlas Biotech Limited | 6.3 Billion INR | -169.733% |
| ZIM Laboratories Limited | 3.67 Billion INR | -363.197% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 91.053% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -47.829% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -304.03% |
| Bal Pharma Limited | 3.39 Billion INR | -401.71% |
| Strides Pharma Science Limited | 40.51 Billion INR | 57.989% |
| Venus Remedies Limited | 5.91 Billion INR | -187.751% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 6.258% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -1.058% |
| Shilpa Medicare Limited | 11.51 Billion INR | -47.785% |
| Aarti Drugs Limited | 25.28 Billion INR | 32.693% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 19.682% |
| Suven Life Sciences Limited | 116.92 Million INR | -14454.98% |
| Ind-Swift Limited | 5.02 Billion INR | -238.708% |
| Valiant Laboratories Limited | 1.82 Billion INR | -834.816% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 51.154% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -37.428% |
| Themis Medicare Limited | 3.81 Billion INR | -345.803% |
| Hikal Limited | 17.84 Billion INR | 4.634% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 83.953% |
| Sequent Scientific Limited | 13.69 Billion INR | -24.251% |
| Novartis India Limited | 3.35 Billion INR | -407.923% |
| Wockhardt Limited | 27.89 Billion INR | 38.978% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 74.61% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -4150.996% |
| Neuland Laboratories Limited | 15.58 Billion INR | -9.195% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -1002.463% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -361.726% |